Most compounding and concentrates firms saw positive results in 2024. And in recent interviews, executives with those companies said they're hoping to keep those good vibes rolling into 2025.
Kirin is stepping up investment in pharmaceutical, health food, and cosmetics businesses due to secular volume decline in the domestic beer market. Management has completed the divestiture process of ...
RSKD's 3Q24 results showed solid revenue growth, improved EBITDA, and strong new product adoption, reinforcing confidence in its growth story. Read more here.